PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Both yoy net incomes decline, with CRVO at -1014.04%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
5.37%
Less D&A growth vs. CRVO's 13.41%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
42.67%
Deferred tax of 42.67% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-15.52%
Negative yoy SBC while CRVO is 36.16%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2.45%
Slight usage while CRVO is negative at -243.85%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Both negative yoy AP, with CRVO at -293.14%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
389.89%
Some yoy usage while CRVO is negative at -137.13%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-15.52%
Negative yoy while CRVO is 82990.38%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Both yoy CFO lines are negative, with CRVO at -141.54%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
51.76%
CapEx growth of 51.76% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while CRVO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
Growth of 169.66% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
253.33%
We expand invests by 253.33% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
100.00%
Debt repayment growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-79.28%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.